Naslov
Reduced renal function strongly affects survival and thrombosis in patients with myelofibrosis

Autori
Lucijanić, Marko ; Krečak, Ivan ; Galušić, Davor ; Sedinić, Martina ; Holik Hrvoje ; Periša, Vlatka ; Morić Perić, Martina ; Zekanović, Ivan ; Štoos- Veić, Tajana ; Kušec, Rajko

Izvornik
Annals of hematology (0939-5555) 100 (2020); 32862283, 7

Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni

Ključne riječi
JAK2 ; Myeloproliferative neoplasm ; Renal function ; Survival ; Thrombosis.

Sažetak
We retrospectively investigated a cohort of 176 myelofibrosis patients (128 primary-PMF ; 48 secondary-SMF) from five hematology centers. The presence of chronic kidney disease (CKD) was determined in addition to other clinical characteristics. CKD was present in 26.1% of MF patients and was significantly associated with older age (P < 0.001), higher WBC (P = 0.015), and its subsets (neutrophil, monocyte, and basophil counts), higher platelets (P = 0.001), lower albumin (P = 0.018), higher serum uric acid (P = 0.001), higher LDH (P = 0.022), and the presence of CV risk factors (P = 0.011). There was no significant association with driver mutations, degree of bone marrow fibrosis, PMF/SMF, or DIPSS risk categories (P > 0.05 for all analyses). The presence of CKD was significantly associated with shorter time to arterial (HR = 3.49 ; P = 0.041) and venous thrombosis (HR = 7.08 ; P = 0.030) as well as with shorter overall survival (HR 2.08 ; P = 0.009). In multivariate analyses, CKD (HR = 1.8 ; P = 0.014) was associated with shorter survival independently of the DIPSS (HR = 2.7 ; P < 0.001) ; its effect being more pronounced in lower (HR = 3.56 ; P = 0.036) than higher DIPSS categories (HR = 2.07 ; P = 0.023). MF patients with CKD should be candidates for active management aimed at the improvement of renal function. Prospective studies defining the optimal therapeutic approach are highly needed.

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti

POVEZANOST RADA